Karyopharm Therapeutics, Inc.
(NASDAQ : KPTI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.08%109.411.1%$637.77m
GILDGilead Sciences, Inc.
1.66%75.570.9%$577.68m
AMGNAmgen Inc.
1.13%176.901.1%$506.89m
REGNRegeneron Pharmaceuticals, Inc.
1.52%388.952.7%$352.74m
BIIBBiogen Inc.
1.36%327.941.2%$335.33m
ALXNAlexion Pharmaceuticals, Inc.
2.36%115.761.9%$262.11m
VRTXVertex Pharmaceuticals Incorporated
2.34%145.861.9%$218.93m
BLUEBluebird Bio, Inc.
-0.76%182.9516.1%$207.25m
ILMNIllumina, Inc.
2.70%216.553.5%$180.07m
ALNYAlnylam Pharmaceuticals, Inc
1.56%125.5910.0%$167.77m
AAgilent Technologies, Inc.
1.64%67.601.5%$158.47m
NKTRNektar Therapeutics
3.36%56.906.1%$157.89m
INCYIncyte Corporation
0.46%96.412.5%$142.11m
BMRNBioMarin Pharmaceutical Inc.
5.07%93.024.4%$114.48m
JUNOJuno Therapeutics, Inc.
1.16%44.6813.5%$102.38m

Company Profile

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.